Daily Briefing – May 11: space-defense leadership meets oil/geopolitical pressure, while biotech IPOs, FDA dates and drone earnings keep the small-cap tape alive

The May 11 setup is less about one isolated headline and more about a crowded high-beta rotation being tested by macro pressure. Space-defense remains the most active theme after Rocket Lab’s record Q1 revenue of $200.3 million, record backlog of $2.2 billion and Q2 revenue guidance of $225 million-$240 million. Redwire continues to support the same trade with Q1 revenue of $97.0 million, up 57.9% year over year, and reaffirmed 2026 revenue guidance of $450 million-$500 million. BlackSky keeps the space-AI lane alive after Q1 revenue of $20.8 million and raised 2026 revenue guidance to $130 million-$150 million, while HawkEye 360’s NYSE debut under $HAWK adds a fresh public pure-play in space-based signals intelligence after a $416 million IPO. On the drone/defense side, Red Cat reported Q1 revenue of $15.5 million, up 849% year over year, while Kratos posted Q1 revenue of $371.0 million, 22.6% growth, a 1.6x book-to-bill ratio and higher FY2026 guidance. Small-cap AI is still tradable but less forgiving: SoundHound AI delivered record Q1 revenue of $44.2 million and reaffirmed 2026 revenue guidance of $225 million-$260 million, while BigBear.ai reported Q1 revenue of $34.4 million, gross margin expansion to 34.0% and backlog of $281.9 million. In biotech, Odyssey’s $279 million IPO, Inhibrx’s May 11 HexAgon clinical update, Zymeworks’ August 25 zanidatamab PDUFA, Avalo’s LOTUS/financing setup and REGENXBIO’s ASGCT presentations keep the calendar active. Cannabis remains a policy watch after the Federal Register notice set the DEA marijuana rescheduling hearing to begin June 29, 2026, while oil/geopolitical tension adds a heavier macro filter to Monday’s tape.

Main single-stock stories
  • RKLB— Rocket Lab remains the space-basket leader after record Q1 revenue of $200.3 million, record backlog of $2.2 billion and Q2 revenue guidance of $225 million-$240 millionSpace
  • RDW— Redwire reported Q1 revenue of $97.0 million, up 57.9% YoY, with gross margin improvement and reaffirmed 2026 revenue guidance of $450 million-$500 millionSpace Defense
  • BKSY— BlackSky stays in the space-AI lane after Q1 revenue of $20.8 million and raised 2026 revenue guidance to $130 million-$150 millionSpace AI
  • HAWK— HawkEye 360’s NYSE debut gives traders a new space-intelligence ticker after the company raised $416 million in its IPO under the symbol $HAWKSpace IPO
  • RCAT— Red Cat reported Q1 revenue of $15.5 million, up 849% year over year, with gross margin improving to 12.7% from negative territory last yearDrones
  • KTOS— Kratos reported Q1 revenue of $371.0 million, up 22.6%, with 30.9% organic growth in Unmanned Systems and increased FY2026 guidanceDefense
  • SOUN— SoundHound AI reported record Q1 revenue of $44.2 million, up 52%, while reaffirming 2026 revenue guidance of $225 million-$260 millionAI Software
  • BBAI— BigBear.ai reported Q1 revenue of $34.4 million, gross margin of 34.0% and backlog of $281.9 million, keeping the focus on national-security AI executionDefense AI
  • INBX— Inhibrx is a key biotech watch after scheduling May 11 interim Phase 2 HexAgon data for INBRX-106 plus pembrolizumab in first-line HNSCCBiotech Data
  • ZYME— Zymeworks stays on the FDA catalyst list after Jazz’s zanidatamab-based sBLA received Priority Review with an August 25, 2026 PDUFA datePDUFA
Macro & tape pressure
  • Oil and geopolitics matter— Monday’s tape starts with a heavier macro filter as oil strength and Middle East tension can pressure risk appetite and inflation-sensitive groupsMacro
  • Space is now an execution trade— RKLB, RDW, BKSY and HAWK keep investor attention on launch, satellites, intelligence and defense demand, but numbers now matter more than themeSpace
  • Defense backlog is being repriced— KTOS, RCAT, BBAI and the wider drone group are being judged on whether orders convert into revenue, margin and cash-flow improvementDefense
  • AI remains selective— SOUN and BBAI both have real revenue, but the market is watching acquisition integration, organic growth, losses, cash burn and backlog qualityAI
  • Biotech funding window is alive— Odyssey’s upsized IPO and Avalo’s financing show capital is available, but investors are still penalizing unclear data, dilution and weak balance sheetsBiotech
  • FDA calendar is getting crowded— ZYME, BIIB/ESAIY and other healthcare names now carry visible August regulatory dates that can influence sector positioningFDA
  • Cannabis catalyst remains alive— The DEA marijuana rescheduling hearing is scheduled to begin June 29, 2026, keeping TLRY, CGC, CRON, MSOS and IIPR on watchCannabis
Themes & rotation
  • Space-defense still leads— Rocket Lab, Redwire, BlackSky and HawkEye keep the public-market space theme focused on launch, satellite infrastructure, signals intelligence and defense demandSpace
  • Drones are no longer a side theme— Red Cat and Kratos are pushing the rotation toward unmanned systems, tactical procurement, battlefield technology and repeatable manufacturing scaleDrones
  • Backlog quality matters— The strongest stories now need more than backlog headlines: traders want funded work, execution visibility, margin improvement and cash disciplineQuality
  • Small-cap AI is under a stricter filter— SOUN and BBAI remain active, but acquisition-heavy growth, defense concentration, losses and conversion risk need to be watched carefullyAI
  • Biotech IPOs are back on radar— Odyssey and HawkEye, although in different sectors, both show that IPO demand exists when the theme is clear and institutional buyers can understand the storyIPO
  • Catalyst trading is back— INBX, ZYME, LEQEMBI IQLIK and cannabis rescheduling put the calendar back at the center of biotech, healthcare and policy-sensitive tradesCatalysts
Tickers to monitor
  • RKLB / RDW / BKSY / HAWK / GSAT / LUNR / PL— The space basket remains active, with focus on launch contracts, satellite intelligence, direct-to-device connectivity, Gen-3 adoption, Neutron and cash runwaySpace
  • RCAT / KTOS / ONDS / AVAV / DRS / RTX— Defense and drone names stay in focus as traders compare revenue scale, battlefield relevance, funded orders, margins and procurement visibilityDefense Drones
  • BBAI / SOUN / AI / PDYN / PATH / SNOW— Small-cap and software AI should be watched through a stricter lens: real revenue, organic growth, integrations, backlog quality and cash runwayAI
  • NVDA / AMD / ARM / AVGO / MU / AMAT— Semis remain central to the broader tape as traders watch data-center demand, China/trade headlines, valuation and upcoming earnings reactionsSemis
  • ODTX / INBX / ZYME / AVTX / STOK / XBI— Biotech remains active across IPOs, clinical data, FDA dates, financing risk and the sector’s ability to absorb new equity supplyBiotech
  • BIIB / ESAIY / LLY / NVO / CYTK / IDYA— Healthcare and biotech catalysts remain on radar through Alzheimer’s, obesity, cardiology, oncology filings and regulatory-review updatesHealthcare
  • TLRY / CGC / CRON / MSOS / IIPR— Cannabis names remain policy-sensitive ahead of the June 29 DEA hearing tied to the broader marijuana rescheduling processCannabis
Tape watch
  • Rocket Lab leadership test— RKLB still has the strongest space tape, but after the post-earnings move the next question is whether backlog and Neutron expectations support follow-throughSpace
  • Redwire margin check— RDW brings strong growth and better gross margin, but traders should still watch losses, liquidity, backlog quality and execution riskSpace Defense
  • HawkEye IPO signal— HAWK gives the market a new public read on space-based signals intelligence and defense-data appetite after a strong debutIPO
  • Red Cat proof phase— RCAT’s 849% revenue growth is eye-catching, but the next test is whether drone orders translate into repeatable production, margins and operating disciplineDrones
  • Kratos funding cycle— KTOS now sits at the intersection of drones, hypersonics, defense electronics and space systems, with guidance and book-to-bill supporting the watch caseDefense
  • SoundHound integration risk— SOUN’s record revenue helps the AI story, but acquisitions, losses and cash usage keep the stock sensitive to margin commentaryAI
  • Inhibrx data watch— INBX’s May 11 HexAgon update can influence the immuno-oncology tape because INBRX-106 is being tested alongside pembrolizumab in first-line HNSCCBiotech Data
  • PDUFA and policy calendar— ZYME’s August 25 zanidatamab date, LEQEMBI IQLIK’s August 24 FDA date and the June 29 DEA hearing all belong on the catalyst calendarCatalysts
Read the full Daily Briefing
Free Course

Run-Up Biotech Masterclass

Learn how to read biotech catalysts, trial results and FDA decisions with a practical framework.

Open
Educational only.
 Tracking Tool

Biotech Catalyst Calendar

Track FDA events, clinical readouts and biotech catalysts with a practical event-driven tool.

Open Archive

Browse the Blog & Archive

Explore articles, biotech deep dives, market notes, reports and archived sector content.

Open Reality Check

Biotech Trading Without the Fairy Tales

A grounded piece on risk, catalysts, dilution, volatility and biotech trading reality.

Open 2026 Watchlist

The New Era – Space, Defense & AI

A thematic watchlist built around military spending, strategic technology and AI-linked trends.

Open Briefing

SPACE AI DEFENCE

A thematic briefing at the intersection of defense, space infrastructure and AI.

Open Top List

Top 10 Defense-Tech Stocks to Watch

A focused list built around defense technology, drones and strategic systems.

Open Top List

Top 5 U.S. Airlines Watchlist

A practical watchlist for pricing power, fuel sensitivity, travel demand and macro tone.

Open Top List

Top 5 Cruise Lines Watchlist

A leisure-focused list centered on major cruise operators and pricing-driven sentiment.

Open
Scanner for active traders

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and sector rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.

Start with the free version. When you upgrade, use SAVE10 to get 10% OFF your first paid period.

Start free – then use SAVE10

No credit card required to start. Apply SAVE10 when upgrading.

ChartsWatcher platform screenshot
Recommended platform

One platform. All your brokers.

Medved Trader connects multiple brokers in one workspace, with professional charts, hotkeys and fast execution — without changing your broker accounts.

A single cockpit for positions, Level II and multi-broker order routing, built for active day and swing traders.

Get 1 Month Free ➔

Multi-broker workflow + customizable layouts in one platform.

Medved Trader platform dashboard
Monica.im Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site

Find out how I use AI on Merlintrader: AI, retail and Merlintrader

Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.

Merlintrader author

Authors: Merlintrader, Jane and Gemini

Author’s note

In every report I share what I see and how I personally interpret it, based on raw data from official company filings, regulatory documents, conference call transcripts and other primary sources where available. Some parts of the research and structure are supported by AI assistants, which help me organize the data, re-check details and improve charts or visual elements. However, any interpretation, opinion and final judgment remain entirely mine, as a trader and not as a licensed financial advisor or registered analyst. Market sentiment can change quickly, while official documents and numbers remain what they are. It is also possible for me to make mistakes: collecting and cross-checking FDA timelines, clinical data, filings and corporate updates is a complex job, so inaccuracies may occur. If you notice something that seems off, feel free to tell me and I will correct it. Please do not treat this report as professional investment advice, but as one more source of information to compare with your own research and with the opinion of qualified professionals.

AI usage disclosure

This report has been prepared using a human + AI workflow. Drafting, editing and data organization are supported by generative AI tools, such as large language models provided by third parties, based on prompts and instructions defined by the author. All sources used are public, and the final selection of data, checks, opinions and conclusions remains with the author, who takes full responsibility for the content.

If you find these reports useful and want to support the project, you can make a voluntary one-time donation via PayPal or Buy Me a Coffee. It helps cover data, tools and hosting costs, so the content can remain independent and freely accessible.

Buy Me a Coffee

Biotech Catalyst Calendar

For a broader and continuously updated view of upcoming biotech catalysts — PDUFA dates, major clinical readouts, regulatory events and key conferences — you can visit the dedicated calendar on Merlintrader.

Open the Biotech Catalyst Calendar